Tiotropium versus placebo for chronic obstructive pulmonary disease (Q24202175)

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat&reg; Soft Mist&trade; Inhaler in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Tolerance to bronchodilating effects of salmeterol in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Meaningful effect size and patterns of response of the transition dyspnea index

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Development and implementation of treadmill exercise testing protocols in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

The effect of tiotropium on exacerbations and airflow in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Improvements with tiotropium in COPD patients with concomitant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT® Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Safety of tiotropium therapy in chronic obstructive lung diseases (COPD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Bronchodilator responsiveness in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Assessing the Impact of Tiotropium on Lung Function and Physical Activity in GOLD Stage II COPD Patients who are Naïve to Maintenance Respiratory Therapy: A Study Protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Lack of protective effect of tiotropium vs induced dynamic hyperinflation in moderate COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Tiotropium for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Premature discontinuation during the UPLIFT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Self-management education for patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Effect of tiotropium on quality of life in COPD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Tiotropium HandiHaler in the treatment of COPD: a safety review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Pulmonary rehabilitation for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Beta2-agonist and anticholinergic drugs in the treatment of lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Review: inhaled anticholinergics increase risk of major cardiovascular events in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

Tiotropium improves FEV1 in patients with COPD irrespective of smoking status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

Tiotropium in COPD patients not previously receiving maintenance respiratory medications

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial)

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

[Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities]

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

1 reference

7 January 2021

Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

Premature discontinuation of patients: a potential bias in COPD clinical trials

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

Cardiovascular safety of tiotropium in patients with COPD.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

EFFICACY OF TIOTROPIUM IN MEN AND WOMEN: 4-YEAR FOLLOW-UP IN THE UPLIFT TRIAL

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009285.PUB2

7 January 2021

10.1002/14651858.CD009285.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22786525

1 reference

Consolidated OpenCitations Corpus – April 2017